Table 2. Characteristics of the neutralizing mAb panel.
| IgG1 | Clones | IGHV | Neutralizing activity NIBRG-14 (µg/ml) | HAI (µg/ml) | H5 competition ELISA % binding to HA | |||
| IC100 | IC50 | IC50 | CR6261-FITC | CR6323-FITC | ||||
| CR6261 | 23 | 1-69 | 0.78 | 0.55 | >50 | 6 | 2 | |
| CR6329 | 1 | 1-69 | 3.1 | 1.9 | >50 | 21 | 3 | |
| CR6342 | 1 | 1-69 | 6.3 | 2.19 | >50 | 12 | 9 | |
| CR6325 | 2 | 1-69 | 6.3 | 2.6 | >50 | 12 | 2 | |
| CR6327 | 1 | 1-69 | 6.3 | 2.6 | >50 | 24 | 12 | |
| CR6323 | 18 | 1-69 | 6.3 | 3.7 | >50 | 2 | -6 | |
| CR6332 | 1 | 1-69 | 13 | 4.5 | >50 | 9 | -5 | |
| CR6334 | 1 | 1-69 | 6.3 | 4.5 | >50 | 15 | 6 | |
| CR6344 | 1 | 1-69 | 25 | 6.3 | >50 | 17 | 8 | |
| CR6307 | 1 | 3-21 | 25 | 8.9 | >50 | 60 | 79 | |
| CR6331 | 1 | 1-69 | 25 | 10 | >50 | 5 | -3 | |
| CR6343 | 1 | 1-69 | 50 | 13 | >50 | 52 | 56 | |
| CR6262 | 3 | 1-69 | 25 | 15 | >50 | 47 | 44 | |
| CR5111 | 8 | 3-21 | >100 | >100 | >50 | 86 | 113 | |
| Neg. Ctrl | NA | 1-69 | >100 | >100 | >50 | 100 | 108 | |
Hemagglutination inhibition (HAI) and microneutralizing assay are described in the methods. Competition ELISA measures the % binding of labelled CR6261 or CR6323 to H5 rHA after pre-incubation with saturating concentrations of unlabelled IgG1.